TY - JOUR
T1 - Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients
AU - Yoshifuji, Ayumi
AU - Toda, Masataro
AU - Oyama, Emi
AU - Nakayama, Tetsuo
AU - Mise, Setsuko
AU - Kikuchi, Kan
AU - Yoshizawa, Mamoru
AU - Kato, Naohiko
AU - Wakai, Haruki
AU - Koibuchi, Kiyoto
AU - Morimoto, Kohkichi
AU - Uwamino, Yoshifumi
AU - Namkoong, Ho
AU - Shibata, Ayako
AU - Wakabayashi, Kaoru
AU - Fujino, Motoko
AU - Komatsu, Motoaki
AU - Mochizuki, Naoki
AU - Kondo, Norihiko
AU - Yoshimura, Akihiko
AU - Hasegawa, Naoki
AU - Ryuzaki, Munekazu
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Japanese Society of Nephrology 2024.
PY - 2024/7
Y1 - 2024/7
N2 - Background: Dialysis patients are susceptible to developing severe coronavirus disease 2019 (COVID-19) due to hypoimmunity. Antibody titers against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) after the primary vaccinations are lower in hemodialysis (HD) patients than in healthy individuals. This study aimed to evaluate the effect of a SARS-CoV-2 booster vaccination in HD and peritoneal dialysis (PD) patients based on antibody titers and cellular and humoral immunity. Methods: Participants of the control, HD, and PD groups were recruited from 12 facilities. SARS-CoV-2 antigen-specific cytokine and IgG-antibody levels were measured. Regulatory T cells and memory B cells were counted using flow cytometry at 6 months after primary vaccination with BNT162b2 and 3 weeks after the booster vaccination in HD and PD patients and compared with those of a control group. Results: Booster vaccination significantly enhanced the levels of antibodies, cytokines, and memory B cells in three groups. The HD group showed significantly higher levels of IgG-antibodies, IL-1β, IL-2, IL-4, IL-17, and memory B cells than those in the control group at 3 weeks after the booster dose. The PD group tended to show similar trends to HD patients but had similar levels of IgG-antibodies, cytokines, and memory B cells to the control group. Conclusions: HD patients had significantly stronger cellular and humoral immune responses than the control 3 weeks after the booster dose. Our findings will help in developing better COVID-19 vaccination strategies for HD and PD patients.
AB - Background: Dialysis patients are susceptible to developing severe coronavirus disease 2019 (COVID-19) due to hypoimmunity. Antibody titers against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) after the primary vaccinations are lower in hemodialysis (HD) patients than in healthy individuals. This study aimed to evaluate the effect of a SARS-CoV-2 booster vaccination in HD and peritoneal dialysis (PD) patients based on antibody titers and cellular and humoral immunity. Methods: Participants of the control, HD, and PD groups were recruited from 12 facilities. SARS-CoV-2 antigen-specific cytokine and IgG-antibody levels were measured. Regulatory T cells and memory B cells were counted using flow cytometry at 6 months after primary vaccination with BNT162b2 and 3 weeks after the booster vaccination in HD and PD patients and compared with those of a control group. Results: Booster vaccination significantly enhanced the levels of antibodies, cytokines, and memory B cells in three groups. The HD group showed significantly higher levels of IgG-antibodies, IL-1β, IL-2, IL-4, IL-17, and memory B cells than those in the control group at 3 weeks after the booster dose. The PD group tended to show similar trends to HD patients but had similar levels of IgG-antibodies, cytokines, and memory B cells to the control group. Conclusions: HD patients had significantly stronger cellular and humoral immune responses than the control 3 weeks after the booster dose. Our findings will help in developing better COVID-19 vaccination strategies for HD and PD patients.
KW - BNT162b2 vaccine
KW - Booster vaccine
KW - COVID-19
KW - Hemodialysis
KW - Hypoimmunity
KW - Peritoneal dialysis
UR - http://www.scopus.com/inward/record.url?scp=85186938299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85186938299&partnerID=8YFLogxK
U2 - 10.1007/s10157-024-02477-8
DO - 10.1007/s10157-024-02477-8
M3 - Article
C2 - 38457030
AN - SCOPUS:85186938299
SN - 1342-1751
VL - 28
SP - 674
EP - 682
JO - Clinical and experimental nephrology
JF - Clinical and experimental nephrology
IS - 7
ER -
